New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma

Bir, Ferda; Çeliker, Duygu; Evyapan, Binnaz Fatma; Yaren, Arzu; Edirne, Tamer

doi:10.3906/sag-1501-68

Cited by 5 publications

(3 citation statements)

References 27 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Desmocollin-3 as a diagnostic biomarker: a. Squamous NSCLC: DSC3 is used as a diagnostic biomarker to differentiate Squamous NSCLC from adenocarcinoma of lung [35][36][37][38][39][40][41][42]. DSC3 is more specific for squamous NSCLC compared to p63 as p63 is also expressed in Adenocarcinoma.…”

Section: Lmentioning

confidence: 99%

Desmocollin-3 and Cancer

Khamar¹

2017

BJSTR

View full text Add to dashboard Cite

Section: Lmentioning

confidence: 99%

Desmocollin-3 and Cancer

Khamar¹

2017

BJSTR

View full text Add to dashboard Cite

“…Nevertheless, we consider that Trk inhibitors could be a therapeutic option in these small num- bers of NTRK1/NTRK2 stained SCC since these inhibitors have been shown to provide effective outcomes in the target treatment of selected patients with NTRK gene fusions [7,8,10,16]. There are a number of studies suggesting that NTRK1/NTRK2 show higher IHC expression in squamous differentiated tissues and SCC [15,[31][32][33][34]. Cho et al [33] evaluated a total of 396 patients with oropharyngeal and non-oropharyngeal head and neck SCC and detected high expression of TrkA (40.9%) and panTrk (43.2%), which was relatively higher in patients with oropharyngeal, p16-positive, and HPV-positive SCC cases.…”

Section: Discussionmentioning

confidence: 99%

Neurotrophic tyrosine receptor kinase (NTRK) 1 and 2 expression in squamous cell carcinoma and squamous intraepithelial lesions of the cervix uteri

Erten¹,

Demir²,

Hakan³

et al. 2021

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Background: Selective tropomyosin receptor kinase (Trk) inhibitors are known to provide promising outcomes in selected tumor patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. In the present study, we aimed to determine whether there was a NTRK1 and NTRK2 expression in cervical squamous cell carcinoma (SCC) and precursor lesions. Materials and methods: A total of 92 formalin-fixed paraffin-embedded tissue samples of cervical SCC, squamous intraepithelial lesion (SIL) and non-neoplastic cervical tissue (NCT) were subjected to immunohistochemical (IHC) staining with NTRK1 and NTRK2 antibodies. These stainings were compared with p16/Ki-67 (IHC) and the low-risk/high-risk Human papillomavirus (HPV) in situ hybridization stainings that were previously administered. Results: In IHC analysis, NTRK1 expression was detected in 3.2% and 12.5% of SCC and cervical intraepithelial neoplasia (CIN)-2 samples, respectively. In addition, NTRK2 expression was detected in 6.5% and 6.3% of SCC and CIN-2 samples, respectively. However, NTRK1/NTRK2 expression was not detected in samples of NCT, CIN-1, and CIN-3. The p16 and Ki-67 expression and high-risk HPV positivity increased as the grade of the lesion increased. Conclusions: The results indicated that both NTRK1 and NTRK2 had no contributory effect on the grading and differentiation of cervical SCC and SIL. We consider that the IHC method is likely to be used for the screening of NTRK gene fusions in patients with cervical SCC. Trk inhibitors are likely to be a favorable therapeutic alternative for this low number of SCC cases with positive NTRK1/NTRK2 staining. Further studies are needed to confirm these ideas.

show abstract

“…This clone has been reported to be 98% specific for ADC. 29 Napsin A is an aspartic proteinase and its expression is thought to be regulated by TTF-1 and is involved in the maturation of surfactant protein B. In some earlier studies, Napsin A has had a higher sensitivity and specificity for ADC than TTF-1.…”

Section: Introductionmentioning

confidence: 99%

<p>A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer</p>

Prabhakaran¹,

Xing

Hocking³

et al. 2019

PLMI

View full text Add to dashboard Cite

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/JUgBeBu__LM Purpose: Classification of non-small cell lung carcinoma (NSCLC), as adenocarcinoma or squamous cell carcinoma, is important both in the diagnosis and treatment of lung cancer. Use of appropriate markers for this identification is crucial in order to conserve patient tissue for further molecular testing that could guide treatment decisions and have prognostic implications. Patients and methods: We constructed tissue microarrays from archival resections of 200 NSCLC that were previously subtyped based on morphology and immunohistochemistry (IHC) in some cases. We performed IHC with three TTF-1 clones (SP141, SPT24 and 8G7G3/1), Napsin A, p40, p63 and CK5/6 and panels of four or two markers that best help identify adenocarcinoma and squamous cell carcinoma were ascertained. Results: Our results showed that the best four-marker panel utilized TTF-1 (clone SP141), Napsin A, p63 and CK5/6 with a sensitivity of 98.3% and high specificity of 91.7%. The best twomarker panel was TTF-1 (clone SP141) and p63 with 96.5% sensitivity and 85.71% specificity. Conclusion: As there are variations in the performance of different clones of TTF-1 IHC antibodies, the clone chosen can increase the diagnostic value in differentiating adenocarcinoma from squamous cell carcinoma. In the panels analyzed, the survival of cases concordant with the diagnosis had longer survival compared to those that were discordant. The difference was however not statistically significant (p>0.05).

show abstract

New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma

Abstract: Our data suggest that Napsin-A, NTRK-2, and Desmocollin-3 are useful markers in the differentiation of nonsmall cell lung cancer.

Cited by 5 publications

References 27 publications

Desmocollin-3 and Cancer

Desmocollin-3 and Cancer

Neurotrophic tyrosine receptor kinase (NTRK) 1 and 2 expression in squamous cell carcinoma and squamous intraepithelial lesions of the cervix uteri

<p>A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer</p>

Contact Info

Product

Resources

About